Literature DB >> 16446599

Use of dexmedetomidine in children after cardiac and thoracic surgery.

Constantinos Chrysostomou1, Sylvie Di Filippo, Ana-Maria Manrique, Carol G Schmitt, Richard A Orr, Alfonso Casta, Erin Suchoza, Janine Janosky, Peter J Davis, Ricardo Munoz.   

Abstract

OBJECTIVE: In this report, we describe our experience with the use of dexmedetomidine in spontaneously breathing as well as in mechanically ventilated patients, after congenital cardiac and thoracic surgery.
DESIGN: Retrospective case series.
SETTING: University hospital, pediatric cardiac intensive care unit. PATIENTS: Thirty-three spontaneously breathing and five mechanically ventilated patients who received dexmedetomidine after cardiothoracic surgery.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Thirty-eight patients, age 8 +/- 1.1 yrs old and weight 29 +/- 3.8 kg, were included. Seven patients (18%) were <1 yr old. Dexmedetomidine was used as a primary sedative and analgesic agent, and when its effect was considered inadequate, despite incremental infusion doses, a rescue agent was administered. The initial dexmedetomidine infusion dose was 0.32 +/- 0.15 microg/kg/hr followed by an average infusion of 0.3 +/- 0.05 microg/kg/hr (range 0.1-0.75 microg/kg/hr). There was a trend toward higher dexmedetomidine infusion requirement in patients <1 yr old compared with older children, 0.4 +/- 0.13 vs. 0.29 +/- 0.17 microg/kg/hr (p = .06). Desired sedation and analgesia were achieved during 93% and 83% of the dexmedetomidine infusion, respectively. According to the intensive care unit sedation scale (score 0-3) and two pain scales (Numeric Visual Analog Scale and Face, Legs, Activity, Cry, and Consolability, score 0-10), the mean sedation score was 1.3 +/- 0.6 (mild sedation) and the mean pain score was 1.5 +/- 0.9 (mild pain). The most frequently rescue drugs administered were fentanyl, morphine, and midazolam. Overall, 49 rescue doses of sedatives/analgesics were given. Patients <1 yr old required more rescue boluses than older children, 22 boluses (3.19 +/- 0.8) vs. 27 boluses (0.8 +/- 0.2, p = .003). Throughout the dexmedetomidine infusion there was no significant change in the systolic and diastolic blood pressure trend. Six patients (15%) had documented hypotension. In three, hypotension resolved with decreasing the dexmedetomidine infusion dose whereas in the other three, hypotension resolved after discontinuing the infusion. Although there was a trend toward lower heart rates, this was not clinically significant. One patient had an episode of considerable bradycardia without hypotension, which resolved shortly after discontinuing the dexmedetomidine infusion. No significant changes in the arterial blood gases or respiratory rates were observed. There was no mortality, and the total intensive care unit length of stay was 19 +/- 2 hrs.
CONCLUSIONS: Our data suggest that dexmedetomidine is a well-tolerated and effective agent for both spontaneously breathing and mechanically ventilated patients following congenital cardiac and thoracic surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446599     DOI: 10.1097/01.PCC.0000200967.76996.07

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  44 in total

1.  Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart disease.

Authors:  Nelson H Burbano; Andrea V Otero; Donald E Berry; Richard A Orr; Ricardo A Munoz
Journal:  Intensive Care Med       Date:  2011-12-13       Impact factor: 17.440

2.  Dexmedetomidine for transport of a spontaneously breathing combative child.

Authors:  Kevin M Watt; Jason Walgos; Ira M Cheifetz; David A Turner
Journal:  Pediatrics       Date:  2012-08-13       Impact factor: 7.124

Review 3.  Incidence of bradycardia in pediatric patients receiving dexmedetomidine anesthesia: a meta-analysis.

Authors:  Maowei Gong; Yuanyuan Man; Qiang Fu
Journal:  Int J Clin Pharm       Date:  2016-12-31

4.  Dexmedetomidine is Associated with an Increased Incidence of Bradycardia in Patients with Trisomy 21 After Surgery for Congenital Heart Disease.

Authors:  Kentaro Ueno; Yumiko Ninomiya; Naohiro Shiokawa; Daisuke Hazeki; Taisuke Eguchi; Yoshifumi Kawano
Journal:  Pediatr Cardiol       Date:  2016-06-06       Impact factor: 1.655

Review 5.  Dexmedetomidine in paediatric anaesthesia.

Authors:  R Lin; J M Ansermino
Journal:  BJA Educ       Date:  2020-07-22

6.  Evaluation of adverse events noted in children receiving continuous infusions of dexmedetomidine in the intensive care unit.

Authors:  Brooke L Honey; Donald L Harrison; Andrew K Gormley; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

7.  Dexmedetomidine use in pediatric intensive care and procedural sedation.

Authors:  Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

8.  Neurologic withdrawal symptoms following abrupt discontinuation of a prolonged dexmedetomidine infusion in a child.

Authors:  Jamie L Miller; Christine Allen; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

9.  Perioperative care following complex laryngotracheal reconstruction in infants and children.

Authors:  Punkaj Gupta; Joseph D Tobias; Sunali Goyal; Jacob E Kuperstock; Sana F Hashmi; Jennifer Shin; Christopher J Hartnick; Natan Noviski
Journal:  Saudi J Anaesth       Date:  2010-09

Review 10.  Clinical uses of dexmedetomidine in pediatric patients.

Authors:  Hanna Phan; Milap C Nahata
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.